CL2013001279A1 - Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso. - Google Patents

Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.

Info

Publication number: CL2013001279A1
Authority: CL; Chile
Prior art keywords: htl1a; neutralizes; encodes; activity; nucleic acid
Prior art date: 2010-11-08

Application number

CL2013001279A

Other languages

English (en)

Inventor

Brenda J Classon

Dimitris Skokos

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-08

Filing date

2013-05-08

Publication date

2014-03-07

2013-05-08 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2014-03-07 Publication of CL2013001279A1 publication Critical patent/CL2013001279A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Mycology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)

CL2013001279A 2010-11-08 2013-05-08 Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso. CL2013001279A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41127610P	2010-11-08	2010-11-08
US201161478309P	2011-04-22	2011-04-22

Publications (1)

Publication Number	Publication Date
CL2013001279A1 true CL2013001279A1 (es)	2014-03-07

Family

ID=45002143

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001279A CL2013001279A1 (es)	2010-11-08	2013-05-08	Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.

Country Status (22)

Country	Link
US (3)	US8642741B2 (es)
EP (1)	EP2638069B1 (es)
JP (2)	JP6076911B2 (es)
KR (1)	KR101896129B1 (es)
CN (1)	CN103261228B (es)
AR (1)	AR083785A1 (es)
AU (1)	AU2011326097B2 (es)
BR (1)	BR112013011245A2 (es)
CA (1)	CA2816799C (es)
CL (1)	CL2013001279A1 (es)
EA (1)	EA030397B1 (es)
IL (1)	IL226172A (es)
JO (1)	JO3375B1 (es)
MX (1)	MX355580B (es)
MY (1)	MY185006A (es)
NZ (2)	NZ610294A (es)
PH (1)	PH12013500912A1 (es)
SG (2)	SG10201504265RA (es)
TW (1)	TWI606118B (es)
UY (1)	UY33715A (es)
WO (1)	WO2012064682A1 (es)
ZA (1)	ZA201304114B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110229471A1 (en)	2008-11-26	2011-09-22	Cedars-Sinai Medical Center	Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
EP2604110B1 (en)	2009-07-08	2016-11-30	Kymab Limited	Animal models and therapeutic molecules
US8766034B2 (en)	2010-09-22	2014-07-01	Cedars-Sinai Medical Center	TL1A model of inflammation fibrosis and autoimmunity
JO3375B1 (ar)	2010-11-08	2019-03-13	Regeneron Pharma	أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
JP5813880B2 (ja)	2011-09-19	2015-11-17	カイマブ・リミテッド	ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
CN104114577A (zh) *	2011-09-30	2014-10-22	特瓦制药澳大利亚私人有限公司	针对TL1a的抗体及其用途
US9253965B2 (en)	2012-03-28	2016-02-09	Kymab Limited	Animal models and therapeutic molecules
US10251377B2 (en)	2012-03-28	2019-04-09	Kymab Limited	Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en)	2012-05-17	2013-11-20	Kymab Ltd	Multivalent antibodies and in vivo methods for their production
CN104781280A (zh) *	2012-11-13	2015-07-15	瑞泽恩制药公司	抗前动力蛋白受体(prokr)抗体及其使用
WO2014106602A1 (en) *	2013-01-02	2014-07-10	Glenmark Pharmaceuticals S.A.	Antibodies that bind to tl1a and their uses
US9788534B2 (en)	2013-03-18	2017-10-17	Kymab Limited	Animal models and therapeutic molecules
MX2015013703A (es)	2013-03-27	2016-08-11	Cedars Sinai Medical Center	Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas.
US9783593B2 (en)	2013-05-02	2017-10-10	Kymab Limited	Antibodies, variable domains and chains tailored for human use
US11707056B2 (en)	2013-05-02	2023-07-25	Kymab Limited	Animals, repertoires and methods
US10208125B2 (en) *	2013-07-15	2019-02-19	University of Pittsburgh—of the Commonwealth System of Higher Education	Anti-mucin 1 binding agents and uses thereof
WO2015010108A1 (en)	2013-07-19	2015-01-22	Cedars-Sinai Medical Center	Signature of tl1a (tnfsf15) signaling pathway
WO2015049517A2 (en)	2013-10-01	2015-04-09	Kymab Limited	Animal models and therapeutic molecules
PE20161092A1 (es) *	2013-11-13	2016-10-28	Pfizer	Anticuerpos especificos para el ligando 1a tipo factor de necrosis tumoral y composiciones y uso de ellos
US10160805B2 (en)	2014-07-11	2018-12-25	New York University	Methods of treating inflammatory bowel disease by administering tumor necrosis factor-like ligand 1A or an agonistic death-domain receptor 3 antibody
WO2016077720A1 (en) *	2014-11-14	2016-05-19	Protein One, Llc	Binding agents and uses thereof
TWI703158B (zh)	2015-09-18	2020-09-01	美商希佛隆公司	特異性結合tl1a之抗體
US20180319889A1 (en) *	2015-11-02	2018-11-08	La Jolla Institute For Allergy & Immunology	Method and medicament for treating airway and/or lung diseases
CR20180365A (es)	2015-12-16	2018-09-28	Amgen Inc	PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR102464372B1 (ko)	2016-03-17	2022-11-04	세다르스-신나이 메디칼 센터	Rnaset2를 통한 염증성 장 질환의 진단 방법
JP7012665B6 (ja) *	2016-05-09	2023-12-14	ブリストル－マイヤーズスクイブカンパニー	Ｔｌ１ａ抗体およびその使用
KR20240128132A (ko)	2016-10-26	2024-08-23	세다르스-신나이 메디칼 센터	중화 항-tl1a 단일 클론 항체
WO2018237159A1 (en)	2017-06-21	2018-12-27	Cephalon, Inc.	Cation exchange chromatography wash buffer
KR20250024101A (ko)	2018-04-25	2025-02-18	프로메테우스 바이오사이언시즈, 인크.	최적화된 항tl1a 항체
RU2689522C1 (ru) *	2018-09-11	2019-05-28	Общество с ограниченной ответственностью "Пальмира Биофарма"	Нуклеотидная последовательность, кодирующая слитый белок, состоящий из растворимого внеклеточного домена человеческого tnfr1 и константной части тяжёлой цепи человеческого igg4
WO2020112890A1 (en) *	2018-11-29	2020-06-04	Cedars-Sinai Medical Center	Rnaset2 compositions and methods of treatment therewith
KR20220088529A (ko)	2019-05-14	2022-06-27	프로메테우스 바이오사이언시즈, 인크.	Tl1a 환자 선택 방법, 시스템 및 장치
CN114901311A (zh)	2019-10-24	2022-08-12	普罗米修斯生物科学公司	Tnf样配体1a（tl1a）的人源化抗体及其用途
US20230287499A1 (en) *	2020-06-03	2023-09-14	Cedars-Sinai Medical Center	Methods and systems for measuring post-operative disease recurrence
CA3207817A1 (en) *	2021-02-18	2022-08-25	Allison LUO	Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
BR112023016574A2 (pt) *	2021-02-18	2023-11-21	Cedars Sinai Medical Center	Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
WO2024239006A1 (en)	2023-05-17	2024-11-21	Genentech, Inc.	Anti-tl1a antibody therapeutic methods
AU2024324300A1 (en)	2023-08-11	2026-02-12	Paragon Therapeutics, Inc.	Tl1a binding antibodies and methods of use
US12473370B2 (en)	2023-10-03	2025-11-18	Absci Corporation	TL1A associated antibody compositions and methods of use
TW202535949A (zh)	2023-12-20	2025-09-16	美商必治妥美雅史谷比公司	靶向IL-18受體β(IL-18RB)之抗體及相關方法
CN120530139A (zh) *	2023-12-29	2025-08-22	成都优洛生物科技有限公司	抗tl1a抗体或其抗原结合片段及应用
KR20250117591A (ko) *	2024-01-26	2025-08-05	퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디.	Tl1a에 특이적으로 결합할 수 있는 항체 및 이의 용도
CN120424214A (zh) *	2024-02-05	2025-08-05	三生国健药业（上海）股份有限公司	一种抗tl1a抗体及其制备方法和用途
CN120818053A (zh) *	2024-04-11	2025-10-21	北京伟德杰生物科技有限公司	Tl1a抗体及其应用
CN120173112A (zh) *	2025-03-11	2025-06-20	江苏荃信生物医药股份有限公司	抗人tl1a单克隆抗体及其相关试剂盒和检测方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7820798B2 (en)	1994-11-07	2010-10-26	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7597886B2 (en)	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US6927044B2 (en)	1998-09-25	2005-08-09	Regeneron Pharmaceuticals, Inc.	IL-1 receptor based cytokine traps
CA2381284A1 (en) *	1999-08-04	2001-02-15	Amgen Inc.	Fhm, a novel member of the tnf ligand supergene family
WO2003048328A2 (en) *	2001-12-03	2003-06-12	Abgenix, Inc.	Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
US20040101920A1 (en)	2002-11-01	2004-05-27	Czeslaw Radziejewski	Modification assisted profiling (MAP) methodology
CA2536086C (en) *	2003-08-20	2013-03-19	University Of Miami	Inhibition of dr3 in the treatment of allergic lung inflammation
US7850962B2 (en)	2004-04-20	2010-12-14	Genmab A/S	Human monoclonal antibodies against CD20
WO2006127900A2 (en) *	2005-05-25	2006-11-30	Biogen Idec Ma Inc.	Tl1a in the treatment of disease
JP5164167B2 (ja) *	2005-08-30	2013-03-13	ユニバーシティーオブマイアミ	免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
ES2398076T3 (es)	2006-06-02	2013-03-13	Regeneron Pharmaceuticals, Inc.	Anticuerpos de alta afinidad contra el receptor de IL-6 humano
EP2183028A2 (en) *	2007-07-25	2010-05-12	AstraZeneca AB	Targeted binging agents directed to kdr and uses thereof - 035
CN101903402B (zh)	2007-11-13	2014-07-16	泰华生物制药美国公司	抗tl1a的人源化抗体
JO3375B1 (ar)	2010-11-08	2019-03-13	Regeneron Pharma	أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)

2011
- 2011-10-31 JO JOP/2011/0327A patent/JO3375B1/ar active
- 2011-11-07 AR ARP110104149A patent/AR083785A1/es unknown
- 2011-11-07 TW TW100140461A patent/TWI606118B/zh not_active IP Right Cessation
- 2011-11-08 MX MX2013005141A patent/MX355580B/es active IP Right Grant
- 2011-11-08 WO PCT/US2011/059675 patent/WO2012064682A1/en not_active Ceased
- 2011-11-08 CN CN201180059396.1A patent/CN103261228B/zh active Active
- 2011-11-08 UY UY0001033715A patent/UY33715A/es unknown
- 2011-11-08 EP EP11785543.7A patent/EP2638069B1/en active Active
- 2011-11-08 AU AU2011326097A patent/AU2011326097B2/en not_active Ceased
- 2011-11-08 SG SG10201504265RA patent/SG10201504265RA/en unknown
- 2011-11-08 NZ NZ610294A patent/NZ610294A/en not_active IP Right Cessation
- 2011-11-08 KR KR1020137014739A patent/KR101896129B1/ko active Active
- 2011-11-08 BR BR112013011245-0A patent/BR112013011245A2/pt not_active Application Discontinuation
- 2011-11-08 US US13/291,145 patent/US8642741B2/en active Active
- 2011-11-08 CA CA2816799A patent/CA2816799C/en active Active
- 2011-11-08 PH PH1/2013/500912A patent/PH12013500912A1/en unknown
- 2011-11-08 SG SG2013034764A patent/SG190176A1/en unknown
- 2011-11-08 MY MYPI2013700737A patent/MY185006A/en unknown
- 2011-11-08 NZ NZ706986A patent/NZ706986A/en not_active IP Right Cessation
- 2011-11-08 JP JP2013537924A patent/JP6076911B2/ja active Active
- 2011-11-08 EA EA201370105A patent/EA030397B1/ru unknown
2013
- 2013-05-05 IL IL226172A patent/IL226172A/en active IP Right Grant
- 2013-05-08 CL CL2013001279A patent/CL2013001279A1/es unknown
- 2013-06-05 ZA ZA2013/04114A patent/ZA201304114B/en unknown
- 2013-12-31 US US14/144,800 patent/US9556277B2/en active Active
2016
- 2016-09-12 JP JP2016177515A patent/JP6272970B2/ja active Active
- 2016-12-15 US US15/380,696 patent/US20170096491A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TWI606118B (zh)	2017-11-21
JP6272970B2 (ja)	2018-01-31
EA201370105A1 (ru)	2013-12-30
CN103261228A (zh)	2013-08-21
IL226172A (en)	2016-08-31
NZ706986A (en)	2016-04-29
CA2816799A1 (en)	2012-05-18
AR083785A1 (es)	2013-03-20
MX355580B (es)	2018-04-06
SG10201504265RA (en)	2015-06-29
KR101896129B1 (ko)	2018-09-07
WO2012064682A1 (en)	2012-05-18
ZA201304114B (en)	2014-02-26
JO3375B1 (ar)	2019-03-13
IL226172A0 (en)	2013-07-31
TW201233796A (en)	2012-08-16
NZ610294A (en)	2015-06-26
JP6076911B2 (ja)	2017-02-08
EP2638069B1 (en)	2018-01-03
US20170096491A1 (en)	2017-04-06
AU2011326097B2 (en)	2015-08-20
BR112013011245A2 (pt)	2020-08-04
US20120114654A1 (en)	2012-05-10
SG190176A1 (en)	2013-06-28
EP2638069A1 (en)	2013-09-18
MY185006A (en)	2021-04-30
UY33715A (es)	2012-05-31
JP2016220693A (ja)	2016-12-28
EA030397B1 (ru)	2018-07-31
PH12013500912A1 (en)	2022-03-30
CN103261228B (zh)	2016-02-10
US9556277B2 (en)	2017-01-31
KR20130132842A (ko)	2013-12-05
US8642741B2 (en)	2014-02-04
CA2816799C (en)	2021-02-16
US20140120109A1 (en)	2014-05-01
JP2014500014A (ja)	2014-01-09
MX2013005141A (es)	2013-07-03
AU2011326097A1 (en)	2013-05-09

Publication	Publication Date	Title
CL2013001279A1 (es)	2014-03-07	Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
CL2013001468A1 (es)	2014-03-21	Anticuerpo humano aislado que se une especificamente al receptor de glucagon humano o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o afeccion asociada con altos niveles de glucosa o cetona en sangre.
CL2013000566A1 (es)	2014-01-24	Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
WO2008121615A3 (en)	2008-12-04	Antibody formulation
CL2013001403A1 (es)	2014-08-08	Anticuerpo monoclonal anti-ccl20 o un fragmento de unión del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de produccion; composicion que lo comprende; y su uso.
CL2013000843A1 (es)	2014-03-07	Anticuerpo aislado o fragmento de union a antigeno del mismo que se une especificamente a cd48 humano y bloquea la interaccion entre cd48 humano y un receptor de cd48; composicion farmaceutica que lo comprende; y su uso.
CL2009000459A1 (es)	2010-12-10	Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
CL2013002039A1 (es)	2014-03-07	Anticuerpo aislado o fragmento del mismo que se une especificamente a il-13; molecula de acido nucleico que lo codifica; vector; celula; composicion farmaceutica que lo comprende; y su uso (div.sol.n°3037-08).
CL2008002444A1 (es)	2009-09-04	Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
CL2013000369A1 (es)	2014-08-08	Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2013000074A1 (es)	2013-12-06	Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
CL2009000379A1 (es)	2012-02-24	Anticuerpo monoclonal aislado especifico contra los ligandos angiopoyetina 1 y 2 del receptor tie 2; fragmento del mismo; molecula de acido nucleico que lo codifica; vector; celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso para inhibir la angiogenesis no deseada tal como cancer.
MX382398B (es)	2025-03-13	Proteinas de union a antigeno st2.
CL2014000631A1 (es)	2014-09-26	Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2014003140A1 (es)	2015-02-27	Anticuerpos aislado que se une a ly6e; metodo de produccion; inmunoconjugado que lo contiene; formulacion farmaceutica que lo contiene y métodos de uso.
UA115439C2 (uk)	2017-11-10	Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
CL2011002482A1 (es)	2012-03-30	Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
EA201492101A1 (ru)	2015-04-30	Антитела против fcrn
IN2014CN03936A (es)	2015-09-04
CL2011002304A1 (es)	2012-04-09	Anticuerpo multiespecifico que comprende un dominio de union al antigeno que se une a egfr y a her3; acido nucleico que lo codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que comprende el anticuerpo; y su uso para tratar el cancer.
CL2008003784A1 (es)	2009-08-14	Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
SA112330988B1 (ar)	2015-07-22	أجسام مضادة تخص trop-2 واستخداماتها
CL2011001994A1 (es)	2012-02-24	Anticuerpo antagonista que se une a la proteína ox40 humana; secuencia de adn que lo codifica; vector de clonación o de expresión que comprende dicho adn codificante; célula huésped que comprende dicho vector de clonación o expresión; proceso de producción de dicho anticuerpo; composición farmacéutica que comprende a dicho anticuerpo; uso médico de dicho anticuerpo; proteína de fusión que comprende a dicho anticuerpo.
BR112015008311A2 (pt)	2017-07-04	conjugados fármaco-proteína
CL2007001840A1 (es)	2008-01-18	Anticuerpo neutralizante que se une a la interleuquina 17 humana (il-17); secuencia de adn que lo codifica; vector y celula huesped que la comprenden; proceso de produccion; preparacion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de patologias mediadas por il-17.